Nektar Therapeutics (NKTR)
Nasdaq · Healthcare · Biotechnology
$42.22−3.12%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.4B
- 52-week range
- $33.40 – $109.00
- 52-week change
- −24.86%
- EPS (trailing)
- −$17.58
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $55.2M (−43.89%)
- Net income
- −$164M
- Operating margin
- −253.7%
- Diluted EPS
- −$9.73
- Free cash flow
- −$209M
From the company’s annual report on SEC EDGAR.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Headquarters: San Francisco, United States · 63 employees · nektar.com